COVID-19 vaccine sales boosted Pfizer earnings well past expectations in the fourth quarter, but the drugmaker is setting a lower-than-expected bar for 2022.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}